Flavonoid compound for use in the treatment of diseases and conditions associated with movement disorders

• Main Authors: Man-Ling Ho, Alleyn Thomas Plowright, Thomas Pfeiffer
• Format: Patent
• Language: English
• Published: 29.11.2023
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

4-(6-oxo-2-(trifluoromethyl)-3,6-dihydrochromeno[7,8-d]imidazole-8-yl)benzonitrile, also known as CF3CN, for use in the treatment of diseases and conditions associated with movement disorder is provided. Preferably, the diseases or conditions are selected from the group: ataxia, cerebral palsy, cervical dystonia, chorea, dystonia, epilepsy, functional movement disorder, Huntington's disease, multiple sclerosis, multiple system atrophy, myoclonus, Parkinson's disease, Parkinsonism, progressive supranuclear palsy, restless leg syndrome, tardive dyskinesia, Tourette syndrome, tremor disorders such as essential tremor, and Wilson's disease. Preferably the condition associated with movement disorder is additionally associated with cognitive impairment. Most preferably the disease or condition is Huntington's disease, Parkinson's disease, and essential tremor. The disease or condition may be a drug-induced movement disorder selected from: serotonin syndrome, acute dystonic reason, neuroleptic malignant syndrome, Parkinsonism, or tardive drug-induced movement disorder. CF3CN may be administered as a single dose or multiple daily doses wherein the dose comprises at least 0.001mg of CF3CN, particularly about 0.001mg to about 500mg.